- About About
-
Medical
Medical
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
-
-
ASA Urges FDA to Implement Good Manufacturing Principles for Vaporization Products
Washington, DC — In a letter to the heads of the U.S. Food & Drug Administration (FDA), the Centers for Disease Control and Prevention, and the U.S. Department of Health and Human Services, Americans for Safe Access calls for the safe regulation of vaporization products and cartridges. As part of its recommendations, ASA urges the FDA to use its regulatory authority to, at minimum, issue guidance that encourages consumers to only buy vaporization products in legal, licensed stores and not on the illicit market.
“The ongoing health crisis attributed to vaping highlights the need for regulations on issues such as third-party testing and accurate labeling,” said Heather Despres, Director of Americans for Safe Access’ Patient Focused Certification program. “For many medical cannabis patients, vaporization is a popular delivery method. Patients have a right to know what is in their medicine, and the FDA should recognize that the only way to prevent further health complications from vaping products is to allow a lawful, regulated marketplace for them to exist.”
ASA recommends that the FDA: 1) develop a recall and adverse event reporting procedure for cannabis and other vape cartridges consistent with other consumer protection laws; 2) promulgate good manufacturing practices for vape cartridges similar to those adopted by the American Herbal Products Association for plant-based material; 3) enforce OSHA guidance and other workplace safety regulations, including sanitization, for vape cartridge manufacturers; and 4) mandate that vape products undergo third-party laboratory testing and certification.
To date, there have been 380 confirmed cases of lung illness and six confirmed deaths attributed to vaping products. However, there has been no consistent e-cigarette or vaping product, substance, or additive that has been identified in all cases, nor has any one product or substance been conclusively linked to lung disease in consumers.
Share